A phase II study of SU011248 [sunitinib] for maintenance therapy in hormone refractory prostate cancer after first line chemotherapy
Latest Information Update: 19 Jul 2022
At a glance
- Drugs Sunitinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms SMART
- 26 Aug 2016 Results published in the Investigational New Drugs
- 26 Aug 2016 Status changed from active, no longer recruiting to completed according to the results published in the Investigational New Drugs.
- 06 Dec 2011 Planned end date changed from 1 Nov 2009 to 1 Nov 2012 as reported by ClinicalTrials.gov.